Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gain Therapeutics (GANX) Accumulated Depreciation (2020 - 2025)

Historic Accumulated Depreciation for Gain Therapeutics (GANX) over the last 6 years, with Q3 2025 value amounting to $169608.0.

  • Gain Therapeutics' Accumulated Depreciation rose 3941.38% to $169608.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $169608.0, marking a year-over-year increase of 3941.38%. This contributed to the annual value of $123357.0 for FY2024, which is 3293.21% up from last year.
  • Gain Therapeutics' Accumulated Depreciation amounted to $169608.0 in Q3 2025, which was up 3941.38% from $159709.0 recorded in Q2 2025.
  • Gain Therapeutics' 5-year Accumulated Depreciation high stood at $169608.0 for Q3 2025, and its period low was $16307.0 during Q1 2021.
  • Moreover, its 5-year median value for Accumulated Depreciation was $71933.0 (2023), whereas its average is $77536.1.
  • Per our database at Business Quant, Gain Therapeutics' Accumulated Depreciation skyrocketed by 11998.45% in 2021 and then soared by 3293.21% in 2024.
  • Over the past 5 years, Gain Therapeutics' Accumulated Depreciation (Quarter) stood at $28389.0 in 2021, then soared by 87.85% to $53329.0 in 2022, then skyrocketed by 74.01% to $92797.0 in 2023, then skyrocketed by 32.93% to $123357.0 in 2024, then skyrocketed by 37.49% to $169608.0 in 2025.
  • Its last three reported values are $169608.0 in Q3 2025, $159709.0 for Q2 2025, and $136778.0 during Q1 2025.